Investors & Media

Stock Info
NASDAQBCLI
Company Information

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Alzheimer’s Disease (AD).

BrainStorm Presentation on New Biomarker Data - NurOwn® at the 32nd International Symposium on ALS/MND

Brainstorm’s December 7, 2021 Presentation on new Biomarker data at the 32nd International Symposium on ALS/MND.

Corresponding Presentation

Recent News
Nov 14, 2022

BrainStorm to request Type A meeting with FDA to facilitate NurOwn's advancement following receipt of a refusal to file letter regarding the company's new Biologics License Application Conference...

Nov 10, 2022

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that the company has received a refusal to file letter...

Nov 7, 2022

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update...

View All

Events
Monday, November 14, 2022
8:00am - 9:00am EST

View All

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds